Neutrophils dominate the immune cell composition in non-small cell lung cancer

Nature Communications

Volumn 8, Issue , 2017, Pages

  Kargl, Julia ^a,b   Busch, Stephanie E ^a   Yang, Grace H Y ^a   Kim, Kyoung Hee ^a   Hanke, Mark L ^a   Metz, Heather E ^a   Hubbard, Jesse J ^a   Lee, Sylvia M ^a   Madtes, David K ^a,c   McIntosh, Martin W ^d   McGarry Houghton, A M ^a,c,e  

^a Clinical Research Division   (United States)

^b MEDICAL UNIVERSITY OF GRAZ   (Austria)

^c UNIVERSITY OF WASHINGTON   (United States)

^d USA   (United States)

^e Division of Human Biology   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

B CELL ACTIVATING FACTOR; CD11B ANTIGEN; CD14 ANTIGEN; CD15 ANTIGEN; CD19 ANTIGEN; CD20 ANTIGEN; CD3 ANTIGEN; CD33 ANTIGEN; CD4 ANTIGEN; CD45 ANTIGEN; CD45RA ANTIGEN; CD56 ANTIGEN; CD68 ANTIGEN; CD69 ANTIGEN; CD8 ANTIGEN; CELL SURFACE MARKER; CHEMOKINE RECEPTOR CCR7; GAMMA INTERFERON; HEPATITIS A VIRUS CELLULAR RECEPTOR 2; HLA DR ANTIGEN; INTERLEUKIN 17; INTERLEUKIN 22; INTERLEUKIN 7 RECEPTOR; OX40 LIGAND; PROGRAMMED DEATH 1 LIGAND 1; T LYMPHOCYTE RECEPTOR BETA CHAIN; TUMOR ANTIGEN;

BIOASSAY; CANCER; CELLS AND CELL COMPONENTS; DESIGN METHOD; FLOW CYTOMETRY; HISTOLOGY; IMMUNE SYSTEM; INHIBITOR; TUMOR;

ARTICLE; B LYMPHOCYTE; BONE MARROW CELL; CANCER GROWTH; CANCER IMMUNOLOGY; CANCER PATIENT; CD25+ T LYMPHOCYTE; CD3+ T LYMPHOCYTE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL COMPOSITION; CELL FUNCTION; CELL POPULATION; COHORT ANALYSIS; COMPARATIVE STUDY; CONTROLLED STUDY; FLOW CYTOMETRY; GENE SEQUENCE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOCOMPETENT CELL; IMMUNOREACTIVITY; LUNG ADENOCARCINOMA; LUNG PARENCHYMA; LYMPHOCYTE FUNCTION; MAJOR CLINICAL STUDY; NEUTROPHIL; PROSPECTIVE STUDY; REGULATORY T LYMPHOCYTE; SQUAMOUS CELL LUNG CARCINOMA; TH1 CELL; TH17 CELL; TUMOR ASSOCIATED LEUKOCYTE; ADENOCARCINOMA; CELL COUNT; IMMUNE SYSTEM; IMMUNOLOGY; LUNG TUMOR; NON SMALL CELL LUNG CANCER; PATHOLOGY; SQUAMOUS CELL CARCINOMA; T LYMPHOCYTE;

ADENOCARCINOMA; CARCINOMA, NON-SMALL-CELL LUNG; CARCINOMA, SQUAMOUS CELL; CELL COUNT; FLOW CYTOMETRY; HUMANS; IMMUNE SYSTEM; LUNG NEOPLASMS; NEUTROPHILS; T-LYMPHOCYTES;

EID: 85011320256     PISSN: None     EISSN: 20411723     Source Type: Journal    
DOI: 10.1038/ncomms14381     Document Type: Article

References (45)

1. Topalian, S. L. et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N. Engl. J. Med 366, 2443-2454 (2012).
2. Brahmer, J. R. et al. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N. Engl. J. Med 366, 2455-2465 (2012).
3. Coussens, L. M. & Werb, Z. Inflammation and cancer. Nature 420, 860-867 (2002).
4. de Visser, K. E., Eichten, A. & Coussens, L. M. Paradoxical roles of the immune system during cancer development. Nat. Rev. Cancer 6, 24-37 (2006).
5. Marx, J. Cancer immunology. Cancers bulwark against immune attack: MDS cells. Science 319, 154-156 (2008).
6. Coussens, L. M., Zitvogel, L. & Palucka, A. K. Neutralizing tumour-promoting chronic inflammation: A magic bullet? Science 339, 286-291 (2013).
7. Chen, Z., Fillmore, C. M., Hammerman, P. S., Kim, C. F. & Wong, K. K. Non-small-cell lung cancers: A heterogeneous set of diseases. Nat. Rev. Cancer 14, 535-546 (2014).
8. Travis, W. D. et al. International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society: international multidisciplinary classification of lung adenocarcinoma: executive summary. Proc. Am. Thorac. Soc. 8, 381-385 (2011).
9. Creelan, B. C. Update on immune checkpoint inhibitors in lung cancer. Cancer Control 21, 80-89 (2014).
10. Cancer Genome Atlas Research Network. Comprehensive genomic characterization of squamous cell lung cancers. Nature 489, 519-525 (2012).
11. Cancer Genome Atlas Research Network. Comprehensive molecular profiling of lung adenocarcinoma. Nature 511, 543-550 (2014).
12. Imielinski, M. et al. Mapping the hallmarks of lung adenocarcinoma with massively parallel sequencing. Cell 150, 1107-1120 (2012).
13. Bindea, G. et al. Spatiotemporal dynamics of intratumoral immune cells reveal the immune landscape in human cancer. Immunity 39, 782-795 (2013).
14. Gentles, A. J. et al. The prognostic landscape of genes and infiltrating immune cells across human cancers. Nat. Med. 21, 938-945 (2015).
15. Tumeh, P. C. et al. PD-1 blockade induces responses by inhibiting adaptive immune resistance. Nature 515, 568-571 (2014).
16. Robins, H. S. et al. Comprehensive assessment of T-cell receptor beta-chain diversity in alphabeta T cells. Blood 114, 4099-4107 (2009).
17. Govindan, R. et al. Genomic landscape of non-small cell lung cancer in smokers and never-smokers. Cell 150, 1121-1134 (2012).
18. Rizvi, N. A. et al. Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer. Science 348, 124-128 (2015).
19. Liu, W. et al. CD127 expression inversely correlates with FoxP3 and suppressive function of human CD4 T reg cells. J. Exp. Med. 203, 1701-1711 (2006).
20. Galon, J. et al. Type, density, and location of immune cells within human colorectal tumours predict clinical outcome. Science 313, 1960-1964 (2006).
21. Mahmoud, S. M. et al. Tumour-infiltrating CD8 lymphocytes predict clinical outcome in breast cancer. J. Clin. Oncol. 29, 1949-1955 (2011).
22. Sallusto, F., Lenig, D., Forster, R., Lipp, M. & Lanzavecchia, A. Two subsets of memory T lymphocytes with distinct homing potentials and effector functions. Nature 401, 708-712 (1999).
23. Radulovic, K. et al. The early activation marker CD69 regulates the expression of chemokines and CD4 T cell accumulation in intestine. PLoS ONE 8, e65413 (2013).
24. Jin, H. T. et al. Cooperation of Tim-3 and PD-1 in CD8 T-cell exhaustion during chronic viral infection. Proc. Natl Acad. Sci. USA 107, 14733-14738 (2010).
25. Gabrilovich, D. I. & Nagaraj, S. Myeloid-derived suppressor cells as regulators of the immune system. Nat. Rev. Immunol. 9, 162-174 (2009).
26. Bronte, V. et al. Recommendations for myeloid-derived suppressor cell nomenclature and characterization standards. Nat. Commun. 7, 12150 (2016).
27. Gabrilovich, D. I., Ostrand-Rosenberg, S. & Bronte, V. Coordinated regulation of myeloid cells by tumours. Nat. Rev. Immunol. 12, 253-268 (2012).
28. Singhal, S. et al. Origin and role of a subset of tumour-Associated neutrophils with antigen-presenting cell features in early-stage human lung cancer. Cancer Cell 30, 120-135 (2016).
29. Sagiv, J. Y. et al. Phenotypic diversity and plasticity in circulating neutrophil subpopulations in cancer. Cell Rep. 10, 562-573 (2015).
30. Iclozan, C., Antonia, S., Chiappori, A., Chen, D. T. & Gabrilovich, D. Therapeutic regulation of myeloid-derived suppressor cells and immune response to cancer vaccine in patients with extensive stage small cell lung cancer. Cancer Immunol. Immunother. 62, 909-918 (2013).
31. Gros, A. et al. Myeloid cells obtained from the blood but not from the tumour can suppress T-cell proliferation in patients with melanoma. Clin. Cancer Res. 18, 5212-5223 (2012).
32. Youn, J. I. & Gabrilovich, D. I. The biology of myeloid-derived suppressor cells: The blessing and the curse of morphological and functional heterogeneity. Eur. J. Immunol. 40, 2969-2975 (2010).
33. Grimaldi, A. M. et al. Abscopal effects of radiotherapy on advanced melanoma patients who progressed after ipilimumab immunotherapy. Oncoimmunology 3, e28780 (2014).
34. Emens, L. A. & Middleton, G. The interplay of immunotherapy and chemotherapy: harnessing potential synergies. Cancer Immunol. Res. 3, 436-443 (2015).
35. Pfirschke, C. et al. Immunogenic chemotherapy sensitizes tumours to checkpoint blockade therapy. Immunity 44, 343-354 (2016).
36. Zhao, W. et al. DeltaNp63, CK5/6, TTF-1 and napsin A, a reliable panel to subtype non-small cell lung cancer in biopsy specimens. Int. J. Clin. Exp. Pathol. 7, 4247-4253 (2014).
37. Grange, C. et al. Phenotypic characterization and functional analysis of human tumour immune infiltration after mechanical and enzymatic disaggregation. J. Immunol. Methods 372, 119-126 (2011).
38. Foster, B., Prussin, C., Liu, F., Whitmire, J. K. & Whitton, J. L. Detection of intracellular cytokines by flow cytometry. Curr. Protoc. Immunol. 6, 24 (2007).
39. Tung, J. W. et al. Modern flow cytometry: A practical approach. Clin. Lab. Med. 27, 453-468, v (2007).
40. Maecker, H. T., McCoy, J. P. & Nussenblatt, R. Standardizing immunophenotyping for the Human Immunology Project. Nat. Rev. Immunol. 12, 191-200 (2012).
41. Kothari, S., Phan, J. H., Stokes, T. H. & Wang, M. D. Pathology imaging informatics for quantitative analysis of whole-slide images. J. Am. Med. Inform Assoc. 20, 1099-1108 (2013).
42. Carlson, C. S. et al. Using synthetic templates to design an unbiased multiplex PCR assay. Nat. Commun. 4, 2680 (2013).
43. Kirsch, I., Vignali, M. & Robins, H. T-cell receptor profiling in cancer. Mol. Oncol. 9, 2063-2070 (2015).
44. Robert, L. et al. CTLA4 blockade broadens the peripheral T-cell receptor repertoire. Clin. Cancer Res. 20, 2424-2432 (2014).
45. Dudley, M. E., Wunderlich, J. R., Shelton, T. E., Even, J. & Rosenberg, S. A. Generation of tumour-infiltrating lymphocyte cultures for use in adoptive transfer therapy for melanoma patients. J. Immunother. 26, 332-342 (2003).